Business Development

Combating COVID-19: Insights from the BIO Europe conference

The Cortellis team regularly attends industry conferences to provide summaries, updates and insights on what’s happening across the life sciences R&D landscape. Here we summarize select proceedings from the spring BIO Europe Conference.*  In the wake of the coronavirus COVID-19 (SARS-CoV-2) pandemic and a lockdown on worldwide travel, the 14th Annual BIO-Europe Spring Partnering meeting […]

Biopharma M&A activity in Q4 2019 47% higher than in Q4 2018

Understand the key drivers and trends of Q4 2019 biopharma business development activities, and get a preview of what’s in store for Q1 2020.   Total disclosed biopharma mergers and acquisitions (M&A) value increased in the fourth quarter of 2019. Disclosed deal value of the top 10 biopharma M&As increased by 47% to $24.9 billion […]

Oncology landscape stays hot for dealmakers

Intense competition for dealmaking in oncology “shows no sign of abating.” That’s the key takeaway from recent analysis developed by Jamie Munro and Helen Dowden, of Clarivate Analytics. Their article, “Oncology dealmaking trends”, was featured in the Biopharma Dealmakers supplement to Nature Biotechnology and Nature Reviews: Drug Discovery. Munro, global practice leader, portfolio and licensing, […]

Busy biopharma M&A activity closed out 2018

During the fourth quarter of 2018, Cortellis Deals Intelligence registered 140 new mergers and acquisitions (M&A) with a total disclosed deal value of $33.1 billion as part of its ongoing coverage of M&A activity in the life sciences sector compared to 153 and $20.3 billion in the third quarter and 151 and $100.7 billion in […]

Biopharma licensing finished with a strong Q4

During the fourth quarter of 2018, Cortellis Competitive Intelligence   registered 1,073 new deals (excluding mergers & acquisitions) with a total disclosed deal value of $46.1 billion as part of its ongoing coverage of licensing activity in the life sciences sector. The totals represented a 7.4% increase from 994 and a 41.4% increase from $27 billion […]

Biopharma M&A engine fires up as new year rings in big deals

Bristol-Myers Squibb (BMS) Co.’s $74 billion bid for Celgene Corp. – which, if it closes, will become the largest M&A in biopharma history – “made for a fascinating opening” to the J.P. Morgan Healthcare Conference (JPM), said Jamie Munro, global practice leader, portfolio and licensing at Clarivate Analytics, especially given Celgene’s historic placemark as the […]

Licensing deals driving the life sciences industry in Q3: notes and trends

During the third quarter of 2018, Cortellis Competitive Intelligence registered 984 new deals (excluding mergers & acquisitions) with a total disclosed deal value of $26 billion as part of its ongoing coverage of licensing activity in the life sciences sector compared to 1,060 and $20.8 billion in the second quarter and 1,158 and $33.6 billion […]

Q3 M&A deals driving the life sciences industry

Trends in M&A volume and deal value During the third quarter of 2018, Cortellis Deals Intelligence registered 131 new mergers and acquisitions (M&A) with a total disclosed deal value of $16 billion as part of its ongoing coverage of M&A activity in the life sciences sector compared to 113 and $104.6 billion in the second […]

Partnering priorities: Do your homework, tell your story

Companies use meetings like BIO CEO and BIO International as sounding boards for fine-tuning company strategy, weighing, for example, the wisdom of taking an asset all the way through to commercialization or teaming up with a strategic partner.